35 results about "Trigonelline" patented technology

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

To provide a charcoal roasting method for coffee beans, which can produce roasted coffee beans having a good flavor and aroma while using low-temperature roasting to prevent damage to trigonelline contained in the green coffee beans. [Solution] The charcoal roasting method for coffee beans according to the present invention includes a loading step in which 15-25 kg of green coffee beans are loaded into a charcoal roaster (4) at loading timing a, when the temperature inside the oven of a charcoal roaster (1) being heated by burning charcoal is higher than a bottom temperature range that includes the bottom temperature, and a termination step in which the roasting of the coffee beans by burning charcoal is terminated at termination timing c, when the temperature inside the oven has risen after dropping to the bottom temperature due to the loading of the green coffee beans, and is within the termination temperature range. The rise time range from bottom timing b, when the temperature has dropped to the bottom temperature, to termination timing c is 600-700 seconds, the bottom temperature range is 95-110°C, and the termination temperature range is 185-195°C.

The invention discloses a trigonelline metformin salt and a preparation method thereof, and the preparation method comprises the following steps: providing a resin column filled with anion exchange resin, treating the resin column with a salt solution for ion replacement activation to obtain an activated resin column, anions of the salt are chloride ions, bromide ions, acetate ions, malate ions, lactate ions, tartrate ions or citrate ions; enabling the trigonelline metformin iodized salt solution to pass through an activated resin column, and selectively collecting the exchanged solution; and carrying out concentration treatment on the collected exchanged solution to obtain the trigonelline metformin salt. In combination with a specific embodiment, compared with a trigonelline metformin iodate, the solubility of the trigonelline metformin salt prepared by the preparation method of the trigonelline metformin salt provided by the invention in water is greatly improved, so that the application range of the trigonelline metformin salt is greatly expanded.

A method for analyzing coffee components includes, in this order, preparation step of preparing a sample solution containing coffee components extracted from coffee beans; dilution step of diluting the sample solution; and detection step of detecting the coffee components by performing liquid chromatography on the diluted sample solution. The detection step includes passing the sample solution through a column packed with a packing material having pentafluorophenylpropyl group, and then detecting trigonelline and pyrocatechol in the passed sample solution by a photodiode array ultraviolet-visible absorbance detector.

The invention discloses a preparation method of trigonelline inner salt and application of the trigonelline inner salt in inhibition of algae growth, the preparation method comprises the following steps: S1, ethyl nicotinate reacts with dimethyl sulfate in methanol to obtain N-methyl ethyl nicotinate monomethyl sulfate salt; s2, stirring and reacting with alkali and thiourea in deionized water while heating to obtain a trigonelline inner salt crude product; and S3, adding an acid to adjust the pH value, adding methanol, filtering, concentrating the solvent, and pulping by using isopropanol to obtain a pure product of the trigonelline inner salt. The method provided by the invention effectively reduces the synthesis cost, avoids the use of a large amount of dangerous reagents, eliminates the residue of toxic reagents, effectively reduces the generation of industrial three wastes, and has the advantages of simple process, convenient operation, cheap and easily available raw materials, high yield, and facilitation of large-scale industrial production. Experimental studies show that the trigonelline inner salt has obvious effects of inhibiting algae growth and killing algae, and can be applied to algicides or inhibiting algal blooms in water.

The present invention generally relates to an improved process for the preparation of Trigonelline or pharmaceutically acceptable salts thereof and to processes for its purification.

The invention provides application of a group of plasma metabolism markers in preparation of a reagent product for pulmonary nodule diagnosis, and relates to the technical field of disease diagnosis reagents. The metabolic marker is prepared from trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin, and the metabolic marker is prepared from the following raw materials: the trigonelline, the 4-methylcatechol, the 2, 4-dinitrophenol, the 3, 4-dihydroxyphenylacetic acid, the N-( According to the application, ultra-high performance liquid chromatography-high resolution mass spectrometry (UPLC / MS) is adopted to carry out metabonomics analysis on plasma samples before and after an early pulmonary nodule operation, and a group of plasma metabolites (trigonelline, 4-methylcatechol, 2, 4-dinitrophenol, 3, 4-dihydroxyphenylacetic acid, N-(2-furfuryl) glycine, mevalonic acid and formononetin) are identified; and the group of metabolites is utilized to form a diagnosis model, so that benign and malignant pulmonary nodules can be accurately diagnosed, and early-stage differential diagnosis and risk assessment are facilitated.

The invention relates to the technical field of natural product extraction, and discloses a green preparation method of high-purity trigonelline. The method comprises the following steps: (1) performing first treatment on a degreased fenugreek seed raw material in an ethanol water solution under 400-500MPa, and removing a solvent to obtain a mixture I; (2) carrying out second treatment on the mixture I in an aqueous two-phase system, and separating to obtain an upper phase solution rich in trigonelline; and (3) sequentially performing ultrafiltration membrane impurity removal, nanofiltration membrane concentration, resin purification, concentration crystallization and drying on the upper-phase solution to obtain the high-purity trigonelline. The method provided by the invention is efficient and low in consumption, the obtained trigonelline is high in purity, and high-selectivity extraction and purification of the trigonelline are realized.

The present application relates to a bacillus velezensis strain JZ01, a microbial agent containing the same and application thereof. The bacillus velezensis strain JZ01 can efficiently antagonize the pathogen of cucumber brown spot and effectively kill root-knot nematodes. Further, the present application also develops a synergist of the strain. It is found that trigonelline can be used as a synergist to significantly increase the efficacy of the strain against the pathogen of cucumber brown spot, and ganoderic acid A can enhance the efficacy of the strain in killing root-knot nematodes, so that a more efficient compound microbial agent can be developed. In addition, the bacillus velezensis strain and the microbial agent containing the same are microbial agents, which are safe and environmentally friendly, and therefore have high industrial value and application prospect.

The composition essentially comprises or comprises trigonelline. The composition can be used in food or beverage applications, pharmaceutical preparations, or dietary supplements. The composition can be administered to a mammal to treat or prevent a mitochondrial-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk. The mitochondrial-related disease or condition is selected from the group consisting of adverse effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, diabetic complications, hyperlipidemia, neurodegenerative disease, cognitive impairment, stress-induced or stress-related cognitive dysfunction, mood disorders, anxiety disorders, age-related neuronal cell death or dysfunction, chronic kidney disease, renal failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathy and dystrophy, and combinations thereof.

The invention belongs to the technical field of active component and target screening, and relates to a purple sweet potato leaf uric acid reducing active component and a potential target and a screening method thereof, the active component comprises rhododendron yellow, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, apigenin, quercetin glycoside, 6-hydroxycoumarin, 6, 6-dihydroxycoumarin, 3, 4, 2', 4 ', 6'-pentahydroxychalcone, 3, 4, 2 ', 4', 6 '-pentahydroxychalcone, 3, 4, 2', 4 '-pentahydroxychalcone, the component A is prepared from 2, 7-dihydroxy coumarin, daphnetin, trigonelline, serotonin, salidroside, sesamin and nicotinamide; the potential target spots comprise INS, PPAR-gamma, IL1-beta, PPAR-alpha, XDH and ABCG2; the method comprises the following steps: preparing purple sweet potato leaves and a sweet potato leaf water extract, determining the uric acid generation inhibition activity of the purple sweet potato leaves through an in-vitro experiment, and carrying out differential metabonomics combined network pharmacology analysis to excavate functional substances for reducing uric acid in the purple sweet potato leaves, thereby providing a material basis for high-valued utilization of the purple sweet potato leaves and development of functional foods for reducing uric acid.

The invention discloses application of trigonelline or pharmaceutical salt thereof in preparation of a medicine for treating obesity-related polycystic ovarian syndrome. In-vivo experiments prove that the trigonelline has an obvious treatment effect on a polycystic ovarian syndrome rat model, and can be used for treating phlegm-dampness type PCOS rats, recovering the estrus cycle of the rats and reducing fasting blood-glucose and insulin resistance conditions of the rats. More importantly, the trigonelline is small in side effect, free of liver and kidney toxicity and incomparable in safety. In addition, the trigonelline plays a role through a key target GLP-1R. Therefore, the trigonelline can be used for preparing the medicine for treating the obese polycystic ovarian syndrome.

The present disclosure relates to a non-therapeutic use of a human milk oligosaccharide (HMO) selected from 3'-sialyllacto-N-tetraose (LSTa), 6'-sialyllacto-N-neotetraose (LSTc) and 3'-sialyl- 3-fucosyllactose (FSL), or a combination thereof, in supporting or improving one or more of brain health, immune system health, gut health, and metabolic health, in a subject, optionally by increasing the production of one or more metabolites selected from the group consisting of of pyridoxine, pyridoxamine, nicotinic acid, N-acetyl-L-glycine, sarcosine, N-acetyl-L-glutamine, N- acetyl-L-aspartic acid, trigonelline, trans-4-hydroxyproline, 3-hydroxybutyric acid (BHB), 4- hydroxybenzoic acid, and N-acetyl-L-tryptophan, in the gastrointestinal tract of the subject.

The disclosure relates to dried coffee extracts that contain relatively large quantities of caffeine (e.g., from about 4-8 wt %), as well as large quantities of other, health-promoting additives such as, for example, 5-caffeoyl quinic acid and trigonelline. Methods of incorporating the dried coffee extracts into beverages and packaging them in kits are also described. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention discloses a theophylline alkaloid salt, a pharmaceutical composition thereof, a preparation method of the theophylline alkaloid salt, and an application of the theophylline alkaloid salt, and belongs to the technical field of pharmaceutical chemistry. Natural alkaloids with definite pharmacological activity, such as stachydrine, betaine, trigonelline, sophocarpidine, choline or berberine, are selected as saline-forming bases, and a series of novel theophylline alkaloid salts are developed. The functional salt formation strategy not only fundamentally changes the traditional theophylline salt formation mode, but also realizes a leap-through breakthrough from single improvement of solubility to synergistic interaction and active attenuation. Through inherent gastric mucosa protection, heart function regulation and other effects of alkaloid, an active attenuation mechanism is constructed, the core toxic and side effects of gastrointestinal irritation, heart excitability and the like caused by theophylline are effectively reduced, the risk of introduction of exogenous sensitizers is avoided, and the bioavailability of theophylline is improved. The clinical problems of narrow therapeutic window and large toxic and side effects of traditional theophylline and salt drugs thereof are effectively solved.

The present invention relates to a universal acid-base water-based zinc plating additive and its application. The universal acid-base water-based zinc plating additive comprises 5wt.% to 20wt.% of polyepichlorohydrin-nitrogen-containing heterocyclic-chain amine, 5wt.% to 10wt.% of trigonelline, 1wt.% to 5wt.% of compound A, 2wt.% to 8wt.% of sodium benzoate, 5wt.% to 10wt.% of tetrahydroxypropylethylenediamine, 0.5wt.% to 5wt.% of glucuronolactone, and the balance is water; wherein compound A is a reactant of nicotinic acid and propane sultone. The universal acid-base water-based zinc plating additive can be used in three production lines: alkaline zinc plating, sulfate zinc plating, and potassium chloride zinc plating. The organic pollutants in the wastewater of the three production lines can be made the same, facilitating unified treatment.

The invention relates to the technical field of electronic atomization, in particular to a composition capable of improving strength, a liquid preparation and a preparation method and application thereof. According to the composition capable of improving the strength, provided by the invention, the composition capable of improving the strength is prepared from trigonelline, magnolol, pepper alcohol and tropine. According to the composition, specific substances are selected as raw material components of the composition capable of improving the strength, under the synergistic effect of the specific substances, the satisfaction of the nicotine-free liquid preparation is improved, and therefore the purpose of physiologically relieving addiction of a user is achieved.

Compositions consist essentially of trigonelline or consist of trigonelline. The compositions can be used in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. The compositions can be administered to a mammal to treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof. The mitochondria-related disease or condition is selected from the group consisting of deleterious effects of aging, stress (e.g., oxidative stress), obesity, overweight, reduced metabolic rate, metabolic syndrome, diabetes mellitus, complications from diabetes, hyperlipidemia, neurodegenerative disease, cognitive disorder, stress-induced or stress-related cognitive dysfunction, mood disorder, anxiety disorder, age-related neuronal death or dysfunction, chronic kidney disease, kidney failure, trauma, infection, cancer, hearing loss, macular degeneration, myopathies and dystrophies, and combinations thereof.

The invention discloses geotrichum candidum fermented coffee beans and a method for improving the quality of coffee by using the geotrichum candidum fermented coffee beans. According to the technical scheme, the Geotrichum candidum is adopted, the strain number of the Geotrichum candidum is CAU266, and the registration number of the Geotrichum candidum in the China Committee for Culture Collection of Microorganisms is CGMCC No. 30151. After the geotrichum candidum CAU266 is adopted for fermentation, the content of caffeine and the content of trigonelline which are bitter substances in the coffee are reduced by 58.5% and 37.1% respectively, and the bitter taste of the coffee is relieved; compared with natural fermentation, the content of 2, 3-butanediol in volatile substances is increased by 230%, so that the coffee has the flavor characteristic of Maotai-flavor liquor. The strain disclosed by the invention can be used as an excellent coffee bean leavening agent and is applied to coffee flavor improvement and quality improvement.

The invention discloses a preparation method of small-particle fructus cannabis, and belongs to the technical field of traditional Chinese medicine treatment. The method comprises the following steps: removing impurities from hulled fructus cannabis; carrying out vacuum low-temperature pretreatment, and then carrying out hot air drying until the moisture content is 3-6%; uniformly mixing the dried fructus cannabis with inert powder, and crushing, wherein the particle size of the inert powder is 10-100 microns; grading and screening to obtain small-particle fructus cannabis with the particle size of 0.18 to 2.0 mm; finally, inert powder is removed through screening; wherein the vacuum low-temperature pretreatment conditions are as follows: the vacuum degree is 0.5-5.0 Pa, the temperature is 5-15 DEG C, and the time is 4-7 hours; the temperature of hot air drying is 125-135 DEG C. According to the method, the total yield is greater than 95%, and the proportion of the small-particle fructus cannabis is greater than or equal to 98%. The content of effective components can be guaranteed, the content of total fatty oil is larger than or equal to 170 mg / g, and the content of trigonelline is larger than or equal to 1.28%.

The application discloses high trigonelline content porphyra haitanensis fermentation liquor and a preparation method and application thereof, and belongs to the technical field of food fermentation processing. The steps are as follows: (1) Pediococcus pentosaceus and Saccharomyces cerevisiae are respectively taken, activated, subcultured, centrifuged to collect the precipitate, washed and redissolved to obtain Pediococcus pentosaceus seed liquid and Saccharomyces cerevisiae seed liquid, mixed to obtain a fermentation inoculum; (2) the porphyra haitanensis is mixed with distilled water, homogenized, glucose is added, sterilized to obtain porphyra haitanensis slurry, the fermentation inoculum is added, fermented, and the supernatant is collected by centrifugation. By adopting the combined fermentation of Pediococcus pentosaceus and Saccharomyces cerevisiae on porphyra haitanensis, the synergistic metabolic effect of the co-culture system is utilized, the biological conversion efficiency and the enrichment amount of trigonelline are improved, and the prepared porphyra haitanensis fermentation liquor can significantly improve the body antioxidant capacity of a senescence model mouse, inhibit the expression of inflammatory factors and a senescence marker p16, and has significant antioxidant and anti-aging effects.

The invention provides application of trigonelline in reducing greenhouse gas emission of ruminant rumen, and relates to the technical field of feed additives. The invention finds that the trigonelline can effectively reduce the emission of greenhouse gases in rumen of ruminants for the first time, and proves that the trigonelline can change the fermentation performance of the rumen of lactating cows, improve the digestibility of nutrient substances, effectively improve the energy utilization efficiency and reduce the yield of methane through an in-vitro fermentation simulation test and an animal feeding verification test. Therefore, the emission of greenhouse gas in the ruminant rumen is reduced; moreover, the trigonelline can also effectively improve the production performance and nutrient substance digestibility of lactating cows, and has dual functions of emission reduction and synergism.

The invention discloses a preparation method of trigonelline, which comprises the following steps: S1, taking nicotinic acid or a derivative thereof as a raw material, taking dimethyl sulfate as a methylation reagent, and reacting in the presence of an organic solvent to generate an intermediate I; s2, reacting the obtained intermediate I with sulfuric acid to obtain a trigonelline crude product; s3, recrystallizing and purifying the trigonelline crude product to obtain a trigonelline pure product. The preparation method comprises the following steps: taking nicotinic acid or a derivative thereof as a raw material, taking dimethyl sulfate as a methylation reagent, reacting in the presence of an organic solvent to generate an intermediate I, obtaining a trigonelline crude product under the action of sulfuric acid, and recrystallizing and purifying the obtained trigonelline crude product to obtain a trigonelline pure product. The process disclosed by the invention has the advantages of good process stability, high reaction yield, high pure product purity, cheap and easily available raw materials, simplicity in operation, high safety, environmental friendliness and the like.

This invention discloses a drug-loaded microcapsule-type controlled-release formulation of trigonelline and its preparation method. The method includes: using microcrystalline cellulose pellets as an inert carrier, sequentially loading a trigonelline drug-loaded layer, a hydroxypropyl methylcellulose isolation layer, and a composite controlled-release membrane layer composed of ethyl cellulose, RS / RL acrylic resin, triethyl citrate, and talc using bottom-spray fluidized bed coating technology; and then filling the mixture into capsules after curing. This invention effectively isolates the drug from the controlled-release membrane layer through the isolation layer and utilizes the RS / RL resin compound to synergistically regulate membrane permeability, achieving stable controlled release of trigonelline. The resulting formulation shows a release rate of no more than 25% in 0.1 mol / L hydrochloric acid after 2 hours, and release rates of 20%-45%, 45%-75%, and 70%-95% after 4 hours, 8 hours, and 12 hours in pH 6.8 buffer solution, respectively. The release behavior is stable and controllable, effectively solving the problem of burst release of highly water-soluble drugs and prolonging the duration of action.

The disclosure relates to dried coffee extracts that contain relatively large quantities of caffeine (e.g., from about 4-8 wt%), as well as large quantities of other, health-promoting additives such as, for example, 5-caffeoyl quinic acid and trigonelline. Methods of incorporating the dried coffee extracts into beverages and packaging them in kits are also described. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention relates to a bacillus velezensis strain JZ01, a fungicide containing the same and application of the bacillus velezensis strain JZ01. The bacillus velezensis strain JZ01 can be used for efficiently antagonizing cucumber brown spot pathogen cercospora, and effectively killing root-knot nematode. Furthermore, the invention also develops a synergist of the bacterial strain, and the research finds that the trigonelline can be used as the synergist to significantly increase the effect of the trigonelline on resistance to cephalosporium, while the ganoderic acid A can enhance the effect of the trigonelline on killing root-knot nematode, so that the trigonelline can be used for developing a more efficient compound bacterial agent. Besides, the bacillus velezensis strain and the fungicide containing the bacillus velezensis strain are microbial preparations and have the advantages of being safe and environmentally friendly, and therefore the bacillus velezensis strain and the fungicide containing the bacillus velezensis strain have high industrial value and application prospects.

The present disclosure relates generally to methods and compositions comprising trigonelline for treating or preventing diseases or conditions associated with muscle decline and / or renal dysfunction. In addition, the invention relates to methods and compositions comprising trigonelline for slowing the progression of glomerular filtration rate (GFR) and / or reducing glomerular vitreous lesion injury and / or increasing lean body mass of the muscle. In addition, methods and compositions comprising trigonelline are disclosed for increasing lean body mass of the muscle and / or increasing muscle fiber size. Also disclosed are methods for increasing the level of at least one nicotinamide adenine dinucleotide and compositions comprising trigonelline. Methods and compositions comprising trigonelline for increasing muscle stem cells and / or reducing muscle stem cell decline are also disclosed.

Disclosed are compositions comprising urolithin, or a pharmaceutically acceptable salt thereof, and trigonelline, or a pharmaceutically acceptable salt thereof, and methods for increasing or maintaining mitochondrial function.

The invention relates to the technical field of biological medicines, in particular to application of trigonelline to prevention and treatment of animal urinary stones. The trigonelline provided by the invention can reduce the occurrence of animal kidney stone. The trigonelline provided by the invention has the functions of remarkably reducing the concentration of urea nitrogen, creatinine and calcium and phosphorus ions in serum of a glyoxylic acid-induced kidney stone mouse and reducing the concentration of serum oxalate. The trigonelline provided by the invention can promote the expression of MYO9A and Cabs1 proteins and inhibit the expression of SPP1, Flt1 and Cdc34 proteins by combining with kidney tissue ZFX proteins, thereby inhibiting abnormal cell proliferation, relieving cell oxidative stress, recovering epithelial barrier, promoting calcium ion transport and finally inhibiting the occurrence of kidney stones.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m / z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and [GSA×Tyr]: [AHA×(an anion having m / z: RMT: polarity of 160.0615:0.830: n)] ratiometric biomarker.